Analysts Anticipate Kindred Biosciences Inc (NASDAQ:KIN) Will Post Earnings of -$0.36 Per Share

Analysts expect Kindred Biosciences Inc (NASDAQ:KIN) to post earnings per share of ($0.36) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Kindred Biosciences’ earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.37). Kindred Biosciences posted earnings of ($0.39) per share during the same quarter last year, which would indicate a positive year over year growth rate of 7.7%. The firm is scheduled to announce its next earnings report after the market closes on Thursday, August 1st.

According to Zacks, analysts expect that Kindred Biosciences will report full-year earnings of ($1.45) per share for the current financial year, with EPS estimates ranging from ($1.60) to ($1.24). For the next financial year, analysts expect that the business will report earnings of ($1.13) per share, with EPS estimates ranging from ($1.30) to ($0.83). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Kindred Biosciences.

Kindred Biosciences (NASDAQ:KIN) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.01). The firm had revenue of $0.52 million during the quarter, compared to analyst estimates of $1.95 million.

A number of brokerages have recently weighed in on KIN. Aegis began coverage on Kindred Biosciences in a report on Wednesday, April 10th. They issued a “buy” rating and a $16.00 price target for the company. Barclays restated a “hold” rating on shares of Bank of Montreal in a research report on Tuesday, June 11th. Stifel Nicolaus set a $154.00 price objective on argenx and gave the company a “buy” rating in a research report on Wednesday, May 22nd. Cantor Fitzgerald set a $135.00 price objective on Zimmer Biomet and gave the company a “buy” rating in a research report on Friday, April 26th. Finally, BidaskClub upgraded Zai Lab from a “sell” rating to a “hold” rating in a research report on Wednesday, June 5th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $14.28.

Large investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP acquired a new position in Kindred Biosciences during the 1st quarter worth $53,000. BNP Paribas Arbitrage SA boosted its position in Kindred Biosciences by 83,433.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,518 shares of the biopharmaceutical company’s stock worth $69,000 after acquiring an additional 7,509 shares during the period. Metropolitan Life Insurance Co. NY boosted its position in Kindred Biosciences by 362.9% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 9,647 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 7,563 shares during the period. Meeder Asset Management Inc. boosted its position in Kindred Biosciences by 16.7% during the 1st quarter. Meeder Asset Management Inc. now owns 11,922 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,706 shares during the period. Finally, Teton Advisors Inc. boosted its position in Kindred Biosciences by 30.8% during the 1st quarter. Teton Advisors Inc. now owns 17,000 shares of the biopharmaceutical company’s stock worth $156,000 after acquiring an additional 4,000 shares during the period. Institutional investors and hedge funds own 65.14% of the company’s stock.

Shares of NASDAQ KIN traded down $0.16 during trading on Friday, reaching $6.17. The stock had a trading volume of 1,606 shares, compared to its average volume of 176,594. Kindred Biosciences has a one year low of $6.31 and a one year high of $15.75. The company has a current ratio of 9.10, a quick ratio of 8.70 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $264.45 million, a PE ratio of -3.88 and a beta of 0.45. The stock has a 50 day simple moving average of $7.91.

About Kindred Biosciences

Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Read More: Bond

Get a free copy of the Zacks research report on Kindred Biosciences (KIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.